Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03727880
Title Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

pancreatic ductal adenocarcinoma

Therapies

Defactinib + Pembrolizumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.